Item 2.02. Results of Operations and Financial Condition.
On January 5, 2021, REGENXBIO Inc. (the "Company") issued a press release (the
"Press Release") regarding program updates and its financial condition for the
year ended December 31, 2020. The disclosure regarding the Company's cash, cash
equivalents and marketable securities as of December 31, 2020 in the subheading
bullets of the Press Release and in the section titled "Financial Guidance" of
the Press Release is furnished in Exhibit 99.1 to this Current Report on
Form 8-K and is incorporated by reference herein.
The Company reports its financial results in accordance with U.S. generally
accepted accounting principles. All financial data in this press release for the
year ended December 31, 2020 is preliminary, as financial close procedures for
the year ended December 31, 2020 are not yet complete. These estimates are not a
comprehensive statement of the financial position of the Company for the year
ended December 31, 2020. Actual results may differ materially from these
estimates as a result of the completion of normal year-end accounting procedures
and adjustments, including the execution of the Company's internal control over
financial reporting, the completion of the preparation and management's review
of the Company's financial statements for the year ended December 31, 2020 and
the subsequent occurrence or identification of events prior to the filing of the
financial results for the year ended December 31, 2020 on Form 10-K with the
Securities and Exchange Commission.
The information in Item 2.02 of this Current Report on Form 8-K, along with the
disclosure regarding the Company's cash, cash equivalents and marketable
securities as of December 31, 2020 in the subheading bullets of the Press
Release and in the section titled "Financial Guidance" of the Press Release,
shall not be deemed "filed" for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to
the liabilities of that section, nor shall it be deemed incorporated by
reference in any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference in such a
filing.
Item 8.01. Other Events.
The Press Release also includes information regarding program updates and
certain anticipated milestones and financial guidance of the Company relating to
periods subsequent to 2020.
A copy of the Press Release is filed as Exhibit 99.1 to this Current Report on
Form 8-K and incorporated herein by reference, with the exception of the
disclosure regarding the Company's cash, cash equivalents and marketable
securities as of December 31, 2020 in the subheading bullets of the Press
Release and in the section titled "Financial Guidance" of the Press Release,
which is furnished as set forth in Item 2.02 above.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit
No. Description
99.1 Press release dated January 5, 2021.
104 The cover page from this Current Report on Form 8-K, formatted in
Inline XBRL.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses